{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:31:57Z","timestamp":1773081117874,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,14]]},"DOI":"10.7759\/cureus.99241","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:42:05Z","timestamp":1765784525000},"source":"Crossref","is-referenced-by-count":1,"title":["Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton\u2019s Tyrosine Kinase Inhibitor: A Case Report"],"prefix":"10.7759","author":[{"given":"Abdul-Razaq N","family":"Al-Shaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ansh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Talha","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zena","family":"Marney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Haematological Oncology","author":"Sive J","year":"2020","unstructured":"Sive J, Foggo V. Haematological Oncology. Kumar and Clark\u2019s Clinical Medicine. Feather A, Randall D, Waterhouse M (ed): Elsevier, London; 2020."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh S","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018, 17:57. 10.1186\/s12943-018-0779-z","journal-title":"Mol Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-47674-4.00124-9","article-title":"Chronic Lymphocytic Leukemia","author":"Awan FT","year":"2020","unstructured":"Awan FT, Byrd JC. Chronic Lymphocytic Leukemia. Abeloff's Clinical Oncology. Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (ed): Elsevier, Philadelphia; 2020. 10.1016\/B978-0-323-47674-4.00124-9"},{"key":"ref4","article-title":"Chronic lymphocytic leukaemia","author":"Barrientos JC","year":"2025","unstructured":"Barrientos JC, Rhodes JM. Chronic lymphocytic leukaemia. BMJ Best Practice. 2025,","journal-title":"BMJ Best Practice"},{"key":"ref5","article-title":"Chronic Lymphocytic Leukemia","author":"Byrd JC","year":"2014","unstructured":"Byrd JC, Flynn JM. Chronic Lymphocytic Leukemia. Abeloff\u2019s Clinical Oncology. Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE (ed): Elsevier, Philadelphia; 2014."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/437643-cryptococcal-infection-in-a-patient-with-chronic-lymphocytic-leukaemia-receiving-acalabrutinib-a-brutons-tyrosine-kinase-inhibitor-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T07:42:06Z","timestamp":1765784526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/437643-cryptococcal-infection-in-a-patient-with-chronic-lymphocytic-leukaemia-receiving-acalabrutinib-a-brutons-tyrosine-kinase-inhibitor-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.99241","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,14]]}}}